The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

Dr. David Braun speaks with Dr. Katy Beckermann on a Nature publication on a neoantigen vaccine that has demonstrated the ability to generate antitumor immunity in RCC.

In this segment, they highlight the logistical and biological considerations that influenced the trial design, the complexities of manufacturing and regulatory approval, the critical role of a multidisciplinary team in antigen selection and peptide synthesis, and the remarkable commitment of patients who underwent extensive procedures to advance the science, all while emphasizing the potential of such vaccines in the minimal residual disease setting.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Emmanuel Antonarakis, MDmCSPC | March 31, 2025
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
View More
Michael Morris, MDmHSPC | March 31, 2025
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Thomas Hope, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Wolfgang Fendler, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.

Video Insights

Clinical discussions with experts in the field

Network Websites